Impact of a dominant intraprostatic lesion (DIL) boost defined by sextant biopsy in permanent I-125 prostate implants on biochemical disease free survival (bDFS) and toxicity outcomes.

CONCLUSIONS: Boost to DIL defined by sextant biopsy with permanent seed prostate implant shows a trend toward improvement of biochemical control in intermediate risk prostate cancer patient without increasing toxicity. PMID: 30935583 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30935583?dopt=Abstract

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - March 31, 2019 Category: Radiology Authors: Guimond E, Lavallée MC, Foster W, Vigneault É, Guay K, Martin AG Tags: Radiother Oncol Source Type: research